2009
DOI: 10.1038/leu.2009.252
|View full text |Cite
|
Sign up to set email alerts
|

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia

Abstract: We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B and 14) between 1984 and 1999. The event-free survival improved significantly (p=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in the 1990s. Approximately 75% of patients treated in the 1980s and 80% in the 1990s were cured. Early intensive triple intrathecal therapy, together with more effective systemic therapy, including con… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

12
235
4
6

Year Published

2010
2010
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 270 publications
(257 citation statements)
references
References 53 publications
12
235
4
6
Order By: Relevance
“…The proportion of patients in our series with T-ALL (13.5%) was comparable to figures reported from studies worldwide including the BFM 95 study (13.3%) [8]. This percentage was also comparable to 13.9%-17.4% of children with T-ALL reported in the last five studies at St Jude Children's Research Hospital [19]. In studies of children with ALL in low-/middle-income countries, the incidence of T-cell ALL ranged from 11.5% to 26.6% [20][21][22].…”
Section: Discussionsupporting
confidence: 87%
“…The proportion of patients in our series with T-ALL (13.5%) was comparable to figures reported from studies worldwide including the BFM 95 study (13.3%) [8]. This percentage was also comparable to 13.9%-17.4% of children with T-ALL reported in the last five studies at St Jude Children's Research Hospital [19]. In studies of children with ALL in low-/middle-income countries, the incidence of T-cell ALL ranged from 11.5% to 26.6% [20][21][22].…”
Section: Discussionsupporting
confidence: 87%
“…This result is similar to our previous study [24]. Compared to studies in high income and low-income countries our finding is relatively high for T-lineage ALL [25][26][27][28][29][30][31][32][33][34][35]. Expression of CD10 and CD34 also varies in different studies ( Table 1).…”
Section: Discussionsupporting
confidence: 76%
“…30 In view of these considerations, the aim should be to optimize treatment for infants with AML, applying the most effective treatment with the lowest side effects. 25,31,32 This implies to use HSCT in CR1 only in selected patients in whom a clear benefit can be expected (further analyses with higher number of patients are needed to define this group). In addition, in future AML-BFM studies, CNS irradiation will be substituted by triple-intrathecal therapy.…”
Section: Discussionmentioning
confidence: 99%